Over the last 7 days, the United States market has risen by 1.9%, and it is up 20% over the past year, with earnings forecasted to grow annually by 19%. In light of these strong market conditions, investors might find opportunities in smaller or newer companies that are often categorized as penny stocks—a term that may sound outdated but still points to potential value. By focusing on those with robust financials and a clear growth path, we explore three examples of penny stocks that could offer both stability and upside potential for investors seeking hidden value in quality companies.

Let's review some notable picks from our screened stocks.

Definitive Healthcare (DH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform both in the United States and internationally, with a market cap of $103.23 million.

Operations: The company's revenue primarily comes from its Internet Information Providers segment, generating $238.26 million.

Market Cap: $103.23M

Definitive Healthcare Corp. faces challenges as a penny stock with a negative return on equity of -124.05% and increasing losses over the past five years. Despite trading at 72.7% below its estimated fair value, it remains unprofitable but has more cash than debt and sufficient cash runway for over three years due to positive free cash flow growth. Recent delistings from major indices and a Nasdaq compliance notice highlight market volatility concerns, while product enhancements aim to strengthen its healthcare data platform's competitiveness in the sector, potentially aiding future revenue growth amidst current financial hurdles.

PMV Pharmaceuticals (PMVP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies for p53 mutations and related cancers in the United States, with a market cap of $70.93 million.

Operations: PMV Pharmaceuticals does not report any revenue segments.

Market Cap: $70.93M

PMV Pharmaceuticals, with a market cap of US$70.93 million, is pre-revenue and currently unprofitable, reporting a net loss of US$18.04 million for Q1 2026. The company benefits from being debt-free and having short-term assets significantly exceeding liabilities, providing it with over a year of cash runway based on current free cash flow trends. While analysts suggest potential stock price growth, PMV's financial challenges include increasing losses over the past five years and negative return on equity. Recent leadership changes may influence strategic direction as Laurie Stelzer assumes the role of Chair at the upcoming Annual Meeting.

Granite Point Mortgage Trust (GPMT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Granite Point Mortgage Trust Inc. is a real estate investment trust that focuses on originating, investing in, and managing senior floating-rate commercial mortgage loans and other debt-related commercial real estate investments in the United States, with a market cap of approximately $71.40 million.

Operations: The company generates revenue primarily through its REIT - Mortgage segment, which contributed $10.27 million.

Market Cap: $71.4M

Granite Point Mortgage Trust, with a market cap of US$71.40 million, is currently unprofitable, reporting a net loss of US$2.43 million for Q1 2026. Despite this, the company's short-term assets significantly exceed its liabilities, providing financial stability and a cash runway exceeding three years if current free cash flow trends continue. The company has reduced its debt-to-equity ratio over five years but still maintains high leverage at 170.8%. While dividends are not covered by earnings or free cash flows, Granite Point continues to distribute them regularly to shareholders amidst stable weekly volatility in stock performance.

Make It Happen

• Unlock our comprehensive list of 324 US Penny Stocks by clicking here.
• Contemplating Other Strategies? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.